Scarica l'app Stockscreener
1.84
0.54%
-0.01
Dopo l'orario di chiusura:
1.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$1.85
Aprire:
$1.91
Volume 24 ore:
1.29M
Relative Volume:
1.07
Capitalizzazione di mercato:
$340.92M
Reddito:
-
Utile/perdita netta:
$-222.39M
Rapporto P/E:
-1.3868
EPS:
-1.3268
Flusso di cassa netto:
$-193.40M
1 W Prestazione:
+10.18%
1M Prestazione:
-18.22%
6M Prestazione:
-19.65%
1 anno Prestazione:
+170.71%
Intervallo 1D:
$1.80
$1.93
Intervallo di 1 settimana:
$1.66
$1.98
Portata 52W:
$0.6607
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.84 | 342.78M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora Therapeutics (NMRA): Stock Holds Steady at $1.85 as Key Support and Resistance Levels TightenGap Down Bounce Plays - Newser
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Stock Navigates Tight RangeTrader Community Signals - Newser
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target - TipRanks
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Inside INdiana Business - FinancialContent
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
William Blair Maintains Neumora Therapeutics(NMRA.US) With Buy Rating - Moomoo
Neumora (NASDAQ: NMRA) ends Q1 2026 with $147M cash and key Phase 3 data ahead - Stock Titan
Neumora Therapeutics Q1 2026 Earnings Report - MarketBeat
Neumora (NASDAQ: NMRA) trims Q1 2026 loss and funds runway into Q3 2027 - Stock Titan
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Depression drug data due this quarter as Neumora cash lasts to 2027 - Stock Titan
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Why Neumora Therapeutics (NMRA) might be the steady performer you need (Technical Strength) 2026-05-06VWAP Deviation - Newser
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
Invus and Avicenna holdings disclosed in Neumora Therapeutics (NASDAQ: NMRA) filing - Stock Titan
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neumora Therapeutics (NMRA) price target increased by 19.25% to 9.33 - MSN
Stifel Maintains Neumora Therapeutics (NMRA) Hold Recommendation - MSN
Mizuho Securities Remains a Buy on Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pr - Benzinga
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
NMRA Technical Analysis | Trend, Signals & Chart Patterns | NEUMORA THERAPEUTICS INC (NASDAQ:NMRA) - ChartMill
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Neumora Therapeutics (NASDAQ: NMRA) sets 2026 proxy votes on board, auditor and executive pay - Stock Titan
Neumora Therapeutics (NMRA) is among the best penny stocks set to explode - MSN
Neumora Therapeutics (NMRA) Stock Turns Bearish on Neumora Therapeutics (NMRA) (+1.48%) 2026-04-15Risk Management - Cổng thông tin điện tử tỉnh Lào Cai
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE) - The Globe and Mail
NMRA Q4 2025 Earnings: Neumora Therapeutics misses EPS estimates, reports no revenuePopular Market Picks - Xã Thanh Hà
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode - Insider Monkey
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Rally Mode: Is Neumora Therapeutics Inc forming a breakout patternInflation Watch & Growth Oriented Trade Recommendations - baoquankhu1.vn
Short Squeeze: Does Neumora Therapeutics Inc stock have upside surprise potentialEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Is Neumora Therapeutics (NMRA) Stock Good for Long Term | Price at $2.12, Up 6.00%Community Buy Signals - UBND thành phố Hải Phòng
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neumora Therapeutics Inc Azioni (NMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):